multiple myeloma
Conditions
Interventions
newly diagnosed multiple myeloma patients/ healthy donors:None
Sponsors
The second hospital of Dalian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 18 years old = Age = 65 years old, regardless of gender VCD or VRD (which can be combined with daretouzumab) is used to induce the treatment of newly diagnosed multiple myeloma patients who intend to collect autologous hematopoietic stem cells for 3-4 courses or healthy donors who provide hematopoietic stem cells for allogeneic transplantation The score of ECOG physical state is =2 No serious complications, such as liver failure, renal failure, heart failure, etc. Non-pregnant and lactating women Be able to understand the test plan, follow the doctor's advice and sign the informed consent form.
Exclusion criteria
Exclusion criteria: Patients with relapsed and refractory multiple myeloma Have a history of arterial or venous thrombosis or thrombophilia in the past year Allergic to G-CSF or plerixafor Active infectious diseases, such as HBV, HCV and tuberculosis Serious diseases that may limit patients' participation in this trial (such as advanced infection, uncontrollable diabetes, severe cardiac insufficiency or myocardial infarction, hepatic and renal insufficiency, etc.) Those who are participating in other clinical trials or have participated in clinical trials of other drugs within 3 months Active malignant tumor Pregnant or lactating women Unable to understand or follow the research plan Any other circumstances that the researcher considers inappropriate to participate in this experiment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CD34+ cell number; | — |
Countries
China
Contacts
Public ContactJisong Yan
The second hospital of Dalian Medical University
Outcome results
None listed